Clinical Trial Update: Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study evaluating T-cell responses to pembrolizumab in advanced non-small cell lung cancer, currently not yet recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Rabin Medical Center | Conditions: NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC Stage IV Without EGFR/ALK Mutation | Phase 2 | Status: NOT_YET_RECRUITING